What is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone that stimulates pituitary GH release and downstream IGF-1. It belongs with GHRH analogs rather than ghrelin-receptor GHRPs such as ipamorelin, GHRP-2, or GHRP-6. [33][34]

The molecule is built around an upstream endocrine signal: cue the pituitary, raise GH pulsatility, and let downstream IGF-1 and metabolic effects carry the clinical question. That upstream position is why glucose, IGF-1, fluid retention, and growth-signal monitoring matter. [33][12]

Product names matter for tesamorelin. EGRIFTA SV and EGRIFTA WR are both tesamorelin products, but they are different formulations with different dose, reconstitution, storage, and administration instructions. The molecule should be understood together with the specific product form. [33][34]

What Tesamorelin is investigated for

Tesamorelin evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Visceral fat reduction in HIV lipodystrophy

Injectable

86% Strong

Visceral-fat reduction in HIV-associated lipodystrophy is the highest-confidence tesamorelin use and should stay population-specific. [33][2][5]

Human evidence

Randomized trials and labeling support reduced excess abdominal fat in adults with HIV-associated lipodystrophy. [33][2][5]

Animal / mechanistic evidence

The GHRH mechanism stimulates GH/IGF-1 signaling, which is tied to the visceral-fat effect and monitoring needs. [33][2][5]

GH-axis stimulation and IGF-1 response

Injectable

68% Moderate

The GH/IGF-1 mechanism is strong, but hormone response alone does not establish broad wellness benefit. [33][12]

Human evidence

Human labeling and trials show GH-axis activity and IGF-1 response, but outcome claims depend on the population studied. [33][12]

Animal / mechanistic evidence

GHRH receptor agonism explains the GH and IGF-1 response. [33][12]

Fat and lean-mass outcomes outside HIV lipodystrophy

Injectable

50% Emerging

Outside HIV lipodystrophy, fat and lean-mass claims should stay study-specific and monitored rather than generalized to healthy-aging use. [14][23]

Human evidence

Small randomized studies in obese adults with reduced GH secretion and in adults with HIV report fat, lean-mass, or muscle-fat findings, but populations and endpoints differ from general wellness use. [14][23][16]

Animal / mechanistic evidence

GHRH receptor agonism and downstream GH/IGF-1 signaling provide the fat and lean-mass rationale. [33][12]

Liver fat and NAFLD

Injectable

50% Emerging

Liver-fat claims should stay HIV-associated NAFLD-specific until broader liver endpoint data exist. [24][26]

Human evidence

Randomized HIV-associated NAFLD studies report liver-fat and fibrosis-related signals, but hard liver outcomes and broader populations remain uncertain. [17][24][26]

Animal / mechanistic evidence

GH-axis and visceral-fat effects provide a plausible metabolic link. [17][24]

Cognitive function

Injectable

38% Preliminary

Cognitive findings are exploratory and should not be presented as cognitive enhancement. [13][30]

Human evidence

Small GHRH and tesamorelin studies have evaluated cognitive or neurocognitive endpoints, but findings remain exploratory. [13][15][30]

Animal / mechanistic evidence

GH/GHRH signaling gives a plausible neuroendocrine rationale, but it is not a direct cognitive-enhancement mechanism. [13][15]

Evidence snapshot

Overall confidence

Strong

84%

The approved HIV-lipodystrophy visceral-fat indication is backed by randomized trials and labeling. Off-label body-composition, liver-fat, or wellness uses need separate, lower-confidence framing. [33][2][5]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

85%

Human evidence

Strong

Randomized trials and FDA labeling support visceral adipose tissue reduction in HIV-associated lipodystrophy. [2][3][5]

65%

Animal / preclinical

Moderate

Nonclinical pharmacology explains GHRH analog action, while the practical evidence base comes mainly from human trials and labeling. [33]

82%

Mechanism support

Strong

GHRH receptor stimulation links tesamorelin to GH release, IGF-1 elevation, and visceral-fat changes in the approved population. [33][12]

Forms & administration

Tesamorelin administration is label-driven. EGRIFTA SV and EGRIFTA WR are both daily subcutaneous products, but they differ in strength, dose, reconstitution, storage, and substitutability. [33][34]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

EGRIFTA SV is labeled at 1.4 mg subcutaneously once daily; EGRIFTA WR is labeled at 1.28 mg subcutaneously once daily. The formulations are not substitutable. [33][34]

Frequency

Once-daily subcutaneous dosing is the labeled pattern for both EGRIFTA SV and EGRIFTA WR. [33][34]

Timing Considerations

Before-bed timing is common in GH-oriented routines, but a consistent daily injection time matters more than meal timing. Product-specific routines control reconstitution, storage, and abdomen site rotation. [33]

Cycle Length

Common early comparison windows run 12-16 weeks, while labeled treatment can continue with ongoing assessment. Visceral-fat benefit can regress after stopping. [3][33]

What to expect

Weeks 4-8

Injectable label-based treatment may first show waist or abdominal-fullness changes while glucose and IGF-1 labs provide context. [33]

Weeks 12-26

Visceral-fat and waist trends are most meaningful over the clinical-trial window, where pivotal studies used CT-measured VAT. [2][5]

After stopping

Abdominal-fat benefit can move back toward baseline when treatment stops, so maintenance decisions matter. [3]

Safety profile

Tesamorelin has prescription-label safety context for injectable treatment. Practical safety attention belongs on injection-site tolerance, musculoskeletal symptoms, glucose intolerance or diabetes monitoring, IGF-1 elevation, active malignancy, pregnancy, and label-specific contraindications. [33][34]

Common side effects

Injection-site pain or swelling [33]
Joint discomfort [33]
Muscle discomfort [33]

Cautions

Active malignancy [33]
Pituitary-axis conditions [33]
Glucose monitoring [33]

What we don't know

Long-term cardiovascular safety has not been established in labeling. [33]

Who Tesamorelin is not for

Route-specific avoid and medical-review notes:

Active malignancy
Tesamorelin labeling includes active malignancy as a contraindication. [33]
Pregnancy
Tesamorelin is contraindicated in pregnancy because visceral fat reduction offers no benefit and may cause fetal harm. [33]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Documented interactions

Diabetes medications
Injectable tesamorelin can worsen glucose tolerance, so diabetes therapy and glucose labs may need adjustment during treatment. [33]

Theoretical interactions

Other GH-axis agents
GH, GHRPs, or other GHRH analogs can add overlapping IGF-1 and fluid-retention effects with injectable tesamorelin; this is a stack-level safety caution. [33]

Pairing notes

Not recommended with

Other GH-axis secretagogues Injectable

Combining tesamorelin with GHRPs or other GH-axis peptides can stack IGF-1, fluid-retention, glucose, and sports-risk concerns without a labeled combination rationale. [33][38]

Regulatory status

United States

FDA-approved injectable tesamorelin products exist for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That approved label does not cover general weight loss, fitness, anti-aging, or unsupervised compounded-use claims. [32][33][34]

Route	FDA drug approval	503A compounding
Injectable	Approved FDA-approved injectable tesamorelin products exist for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The label does not cover general weight loss, fitness, or anti-aging use. [32][33][34][37]	Not Listed Because FDA-approved injectable tesamorelin products exist, regulatory interpretation should start with the product label. Any compounded version would still be separate from FDA approval for that compounded product. [32][33][34][37]

Injectable

FDA drug approval

Approved

FDA-approved injectable tesamorelin products exist for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The label does not cover general weight loss, fitness, or anti-aging use. [32][33][34][37]

503A compounding

Not Listed

Because FDA-approved injectable tesamorelin products exist, regulatory interpretation should start with the product label. Any compounded version would still be separate from FDA approval for that compounded product. [32][33][34][37]

International

EU/Europe, UK, Canada, and Australia access depends on local brand authorization, indication, and prescribing pathway; the U.S. EGRIFTA label should not be generalized to every market.

Sports & competition

WADA's 2026 Prohibited List treats tesamorelin/GHRF analog use as prohibited under S2; tested athletes should treat injectable use as prohibited without a valid TUE. [38]

How it works

Tesamorelin is a GHRH analog that stimulates pituitary GHRH receptors, increasing pulsatile growth hormone release and downstream IGF-1. In its approved context, that GH-axis signal is tied to reduced excess abdominal visceral fat in adults with HIV-associated lipodystrophy. [33][12][5]

The same pathway explains the label cautions: IGF-1 can rise, glucose tolerance can change, fluid-retention symptoms can occur, and neoplasm history matters. Subcutaneous delivery and the labeled population are part of the mechanism interpretation; it should not be generalized to ordinary weight loss or anti-aging. [33][34]

Research gaps & open questions

What the current literature has not yet settled about Tesamorelin:

Long-term cardiovascular safety beyond available label and extension data remains a key label-level uncertainty. [33]

Off-label body-composition, NAFLD, cognition, and nerve-injury uses need indication-specific outcome evidence. [26][36]

Head-to-head comparisons with modern obesity and metabolic therapies are sparse and should not be inferred from HIV-lipodystrophy trials. [12]

Common questions

What is tesamorelin approved for?

Tesamorelin is approved as an injectable drug to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. [33][34]

Is tesamorelin a general weight-loss drug?

No. It is not for weight-loss management; the strongest evidence is for adults with HIV-associated lipodystrophy. [33]

Is tesamorelin allowed in tested sports?

No. WADA prohibits tesamorelin and other growth hormone releasing factors under S2 unless a valid anti-doping pathway applies. [38]

Myths & misconceptions

Myth

FDA-approved for visceral fat means tesamorelin is approved for anyone who wants fat loss.

Reality

The approval is specific to excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight management. [33]

Myth

EGRIFTA WR and EGRIFTA SV can be substituted milligram for milligram.

Reality

The labels state the formulations have different dosing, reconstitution, storage, and administration instructions and are not substitutable. [34]

History & discovery

Tesamorelin's history is different from many peptide-library entries because it moved from GHRH analog pharmacology into an FDA-approved, narrowly labeled HIV-lipodystrophy drug. [33][2]

Randomized trials tested whether a growth-hormone-releasing factor analog could reduce visceral adipose tissue in adults with HIV-associated abdominal fat accumulation. [2][5]

The approval history made tesamorelin a regulated prescription product for one specific use, not a general weight-loss or anti-aging peptide. [32][33]

EGRIFTA WR labeling continued the same HIV-lipodystrophy indication while later research explored liver fat and other HIV-associated metabolic questions. [34]

Published research 38 studies

[1]

Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.

Current opinion in investigational drugs (London, England : 2000), 2006 Oct. review.

[2]

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

The New England journal of medicine, 2007 Dec 6. human clinical.

[3]

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

AIDS (London, England), 2008 Sep 12. human clinical.

[4]

Tesamorelin, a human growth hormone releasing factor analogue.

Expert opinion on investigational drugs, 2009 Mar. review.

[5]

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Journal of acquired immune deficiency syndromes (1999), 2010 Mar. human clinical.

[6]

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

AIDS (London, England), 2011 Jun 19. human clinical.

[7]

Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2011 Jun. human clinical.

[8]

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Drugs, 2011 May 28. review.

[9]

Spotlight on tesamorelin in HIV-associated lipodystrophy.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2011 Dec 1. review.

[10]

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.

HIV/AIDS (Auckland, N.Z.), 2011. review.

[11]

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.

The Annals of pharmacotherapy, 2012 Feb. review.

[12]

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012 Jun. human clinical.

[13]

Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.

Archives of neurology, 2012 Nov. human clinical.

[14]

Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

The Journal of clinical endocrinology and metabolism, 2012 Dec. human clinical.

[15]

Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.

JAMA neurology, 2013 Jul. human clinical.

[16]

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

The Journal of clinical endocrinology and metabolism, 2014 Jan. human clinical.

[17]

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

JAMA, 2014 Jul 23-30. human clinical.

[18]

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

Clinical pharmacokinetics, 2015 Mar. human clinical.

[19]

Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.

Journal of pharmacokinetics and pharmacodynamics, 2015 Jun. human clinical.

[20]

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

PloS one, 2015. human clinical.

[21]

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

PloS one, 2017. human clinical.

[22]

Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2017 Dec. human clinical.

[23]

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

The Journal of frailty & aging, 2019. human clinical.

[24]

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

The lancet. HIV, 2019 Dec. human clinical.

[25]

Tesamorelin.

PubMed, 2012. review.

[26]

Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021 Jun 15. human clinical.

[27]

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

JCI insight, 2020 Aug 20. human clinical.

[28]

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021 Aug 16. human clinical.

[29]

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

AIDS (London, England), 2024 Oct 1. human clinical.

[30]

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

The Journal of infectious diseases, 2025 Jun 2. human clinical.

[31]

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.

Obesity research & clinical practice, 2026 Jan-Feb. review.

[32]

Drugs@FDA/openFDA query for tesamorelin approved products

U.S. Food and Drug Administration / openFDA. database query.

[33]

EGRIFTA SV- tesamorelin kit

DailyMed / National Library of Medicine. official guidance.

[34]

EGRIFTA WR- tesamorelin kit

DailyMed / National Library of Medicine. official guidance.

[35]

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

ClinicalTrials.gov. clinical trial registry.

[36]

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

ClinicalTrials.gov. clinical trial registry.

[37]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[38]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency, 2026. regulatory.